Form 8-K - Current report:
SEC Accession No. 0000950170-22-010892
Filing Date
2022-05-31
Accepted
2022-05-31 07:06:25
Documents
14
Period of Report
2022-05-31
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K axsm-20220531.htm   iXBRL 8-K 55982
2 EX-99.1 axsm-ex99_1.htm EX-99.1 22862
3 GRAPHIC img36028404_0.jpg GRAPHIC 55046
  Complete submission text file 0000950170-22-010892.txt   274351

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT axsm-20220531.xsd EX-101.SCH 2469
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT axsm-20220531_pre.xml EX-101.PRE 9441
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT axsm-20220531_lab.xml EX-101.LAB 12798
8 EXTRACTED XBRL INSTANCE DOCUMENT axsm-20220531_htm.xml XML 4540
Mailing Address 22 CORTLANDT STREET, 16TH FLOOR NEW YORK NY 10007
Business Address 22 CORTLANDT STREET, 16TH FLOOR NEW YORK NY 10007 (212) 332-3241
Axsome Therapeutics, Inc. (Filer) CIK: 0001579428 (see all company filings)

EIN.: 454241907 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37635 | Film No.: 22980418
SIC: 2834 Pharmaceutical Preparations